Hostname: page-component-7b7567c8c-kwt9d Total loading time: 0 Render date: 2026-11-15T08:57:23.990Z Has data issue: false hasContentIssue false

435 Discovering novel atrial fibrillation phenogroups: A multi-algorithm approach using real-world claims data

Published online by Cambridge University Press:  08 May 2026

Louis Li
Affiliation:
Rollins School of Public Health, Emory University
Rameshbabu Manyam
Affiliation:
Department of Biostatistics and Bioinformatics, Emory University School of Public Health, Atlanta, GA, USADepartment of Computer Science, Georgia State University, Atlanta, GA, USA
Alvaro Alonso
Affiliation:
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
Joshua D. Wallach
Affiliation:
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
Amit J. Shah
Affiliation:
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USADepartment of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA Atlanta Veterans Affairs Healthcare System, Decatur, GA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Objectives/Goals: To discover novel phenogroups of atrial fibrillation (AF) from a real-world claims database using a multi-algorithm unsupervised machine learning (ML) approach and to reveal clinical factors associated with each phenogroup using supervised ML. We aim to establish clinically meaningful AF phenogroups to advance precision medicine. Methods/Study Population: We will leverage the Merative MarketScan databases (2016–2024) of real-world claims data with an estimated >600,000 AF patients. Four unsupervised ML clustering techniques will be employed to identify phenogroups: k-means, Gaussian mixture models, agglomerative, and HDBSCAN. Following cluster generation, the algorithms will be evaluated through internal validation via the Davies–Bouldin Index which calculates cluster compactness and separation, and the Adjusted Rand Index to determine stability between algorithms. Then, supervised ML via SuperLearner, which will include advanced algorithms (e.g., gradient boosting machines and support vector machines), will identify clinical factors associated with each phenogroup and will be evaluated using k-fold cross-validation and Shapley values. Results/Anticipated Results: We anticipate that the multi-algorithm approach will yield robust, distinct, and clinically meaningful AF phenogroups. SuperLearner will confirm the key clinical characteristics driving membership in each group (e.g., hypertension and heart failure). These data-driven classifications will provide a robust foundation for subsequent translational analyses. We will perform time-to-event analyses to assess the differential risks of stroke, coronary artery disease and myocardial infarction, heart failure, and rates of healthcare utilization across phenogroups. Next, we will employ the target trial framework to evaluate the comparative effectiveness of anticoagulant therapies on stroke incidence across phenogroups. Discussion/Significance of Impact: This work demonstrates a highly rigorous, multi-algorithm approach to characterize a large, real-world database of AF patients. By constructing novel AF phenogroups, we aim to move beyond the limitations of current AF classifications and advance precision medicine by providing the foundation for individualized therapeutic strategies.

Information

Type
Precision Medicine/Health
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2026. The Association for Clinical and Translational Science